Perpetuum starts pre-clinical stage investigation of it’s proprietary Polydendritic Nano-Adjuvants for novel vaccination strategies.
Perpetuum launches it’s new brand Ombium, a nutritional supplement line targeting metabolic syndrome risk factors.
Perpetuum set to launch the world’s first acne treatment based on it’s recombinant bacteriophage endolysin technology. Dermium is a development, technology & product from our sistercompany Asterion Therapeutics. Read more on dedicated website dermium.bio
Perpetuum opens new division in China for the sales of it’s cosmetic consumer brands throughout APAC.